The natural compound n-butylidenephthalide (BP), which is isolated from the chloroform extract of Angelica sinensis, has been investigated for its antitumoral effects on glioblastoma multiform (GBM) brain tumors both in vitro and in vivo. To determine the mechanism of BP-induced growth arrest and apoptosis, we examined BP-induced changes in gene expression by microarray screening using human GBM brain tumor cells. This analysis identified several BP-inducible genes, including the nuclear receptors NOR-1, Nurr1, and Nur77. Among these genes, Nur77 is particularly interesting because it plays an important role in the apoptotic processes in various tumor cell lines. BP was able to increase Nur77 mRNA and protein expression in a time-dependent manner. After BP treatment in GBM 8401 cells, Nur77 translocated from the nucleus to the cytoplasm, the cytochrome c was released from the mitochondria, and caspase 3 became activated. Furthermore, using Nur77 promoter-luciferase assay, BP increased Nur77 was AP1 related. Inhibition of BP-induced Nur77 expression by Nur77 short interfering RNA blocked BP-induced apoptosis in GBM 8401 cells, suggesting that the induction of Nur77 negatively affected GBM 8401 cell survival. In summary, our results suggest that up-regulation of Nur77 may explain the antitumoral activity of BP in brain tumor cells.

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1471-4159.2008.05432.xDOI Listing

Publication Analysis

Top Keywords

brain tumor
12
gbm 8401
12
nur77
10
glioblastoma multiform
8
gbm brain
8
tumor cells
8
8401 cells
8
gbm
5
orphan nuclear
4
nuclear receptor
4

Similar Publications

Introduction: Treatment options for patients with epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) with disease progression on/after osimertinib and platinum-based chemotherapy are limited.

Methods: CHRYSALIS-2 Cohort A evaluated amivantamab+lazertinib in patients with EGFR exon 19 deletion- or L858R-mutated NSCLC with disease progression on/after osimertinib and platinum-based chemotherapy. Primary endpoint was investigator-assessed objective response rate (ORR).

View Article and Find Full Text PDF

Evaluating the impact of performance status in elderly patients with glioblastoma.

J Clin Neurosci

January 2025

Department of Radiation Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA; Department of Neurosurgery, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14203, USA. Electronic address:

Background: Glioblastoma (GBM) is a common brain tumor with a poor prognosis. There is a paucity of knowledge regarding optimal treatment approaches for elderly patients with GBM who have a relatively good Karnofsky (KPS) or Eastern Cooperative Oncology Group (ECOG) performance status. This study compared treatment outcomes in older patients (≥65) with GBM based on their performance status, either high (KPS ≥ 70 and ECOG < 2) or low (KPS < 70 and ECOG ≥ 2), who underwent hypofractionated radiotherapy (HFRT) (40 Gy in 15 fractions) versus conventional fractionation (60 Gy in 30 fractions).

View Article and Find Full Text PDF

Background: Brain metastases (BMs) are common in human epidermal growth factor receptor 2 (HER2)-positive advanced breast cancer, increasing morbidity and mortality. Systemic therapy for BMs can be effective, with the triple combination of trastuzumab, capecitabine, and tucatinib being a potential standard. More recently, intracranial activity of antibody-drug conjugates has been reported, but the size of individual studies has been small.

View Article and Find Full Text PDF

Hierarchically Engineered Self-Adaptive Nanoplatform Guided Intuitive and Precision Interventions for Deep-Seated Glioblastoma.

ACS Nano

January 2025

Shanghai Frontiers Science Center of Drug Target Identification and Delivery, School of Pharmaceutical Sciences, Shanghai Jiao Tong University, Shanghai 200240, China.

Glioblastoma multiforme (GBM), particularly the deep-seated tumor where surgical removal is not feasible, poses great challenges for clinical treatments due to complicated biological barriers and the risk of damaging healthy brain tissue. Here, we hierarchically engineer a self-adaptive nanoplatform (SAN) that overcomes delivery barriers by dynamically adjusting its structure, surface charge, particle size, and targeting moieties to precisely distinguish between tumor and parenchyma cells. We further devise a AN-uided ntuitive and recision ntervention (SGIPi) strategy which obviates the need for sophisticated facilities, skilled operations, and real-time magnetic resonance imaging (MRI) guidance required by current MRI-guided laser or ultrasound interventions.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!